We recently reported an increased incidence of cirrhosis in hepatitis C virus (HCV)-infected stem cell transplant (SCT) recipients. Here, we describe our experience in the treatment of these patients, which has been, to date, poorly reported in the literature. Among 99 HCV-infected HCT recipients, 36 had HCV-related liver lesions on biopsy requiring therapy. Owing to HCV treatment contraindications, only 61% of patients (22/36) could be treated. In all, 12 patients received more than one course of anti-HCV treatment if they had HCV RNA still detectable after the first course of treatment and no treatment contraindications. Combined therapy (pegylated interferon (IFN): n ¼ 9, or standard IFN: n ¼ 9, in combination with ribavirin) led to sustained virological response in 4/18 (20%) patients as compared to 2/20 (10%) in patients who received IFN alone. Hematological toxicity was more frequent with combined therapy. While anemia responded to erythropoietin and/or dose modification, thrombocytopenia usually led to treatment interruption (n ¼ 3). This study thus highlights the efficacy of combined therapy and emphasizes the fact that the undue safety concerns are not a problem when treating this particular population. 
We recently reported an increased incidence of cirrhosis in hepatitis C virus (HCV)-infected stem cell transplant (SCT) recipients. Here, we describe our experience in the treatment of these patients, which has been, to date, poorly reported in the literature. Among 99 HCV-infected HCT recipients, 36 had HCV-related liver lesions on biopsy requiring therapy. Owing to HCV treatment contraindications, only 61% of patients (22/36) could be treated. In all, 12 patients received more than one course of anti-HCV treatment if they had HCV RNA still detectable after the first course of treatment and no treatment contraindications. Combined therapy (pegylated interferon (IFN): n ¼ 9, or standard IFN: n ¼ 9, in combination with ribavirin) led to sustained virological response in 4/18 (20%) patients as compared to 2/20 (10%) in patients who received IFN alone. Hematological toxicity was more frequent with combined therapy. While anemia responded to erythropoietin and/or dose modification, thrombocytopenia usually led to treatment interruption (n ¼ 3). This study thus highlights the efficacy of combined therapy and emphasizes the fact that the undue safety concerns are not a problem when treating this particular population. A recent prospective study of the European Group for Blood and Marrow Transplantation showed that the prevalence of HCV RNA-positive stem cell transplant (SCT) recipients was 6%. 2 We recently reported the natural history of HCV infection in allogeneic bone marrowtransplanted patients. At a median follow-up of 15.7 years, 15 patients developed biopsy-proven cirrhosis, leading to a cumulative incidence of cirrhosis of 11 and 24% at 15 and 20 years, respectively. HCV infection ranked third, behind infection and graft-versus-host disease (GVHD), as a cause of late death. Moreover, we observed a more rapid rate of liver fibrosis progression in our population as compared with HCV-infected patients who did not receive a transplant. The expected median time to cirrhosis in transplant recipients was about 18 years as compared with 40 years in the control population, and on multivariate analysis, only marrow transplantation emerged as a significant risk factor when the two populations were pooled. 3 Long-term survivors after SCT are thus at high risk for HCV-related complications and treatment of HCV infection becomes critical.
Combined treatment with standard interferon (IFN) or with pegylated IFN (PEG IFN) and ribavirin (RBV) in immunocompetent patients markedly increases sustained virological response rates as compared to IFN monotherapy. [4] [5] [6] [7] It is noteworthy that treatment of HCV-infected SCT recipients has been poorly reported in the literature for two reasons: (i) the incidence of cirrhosis has until recently been underestimated; (ii) the concern that IFN might induce or precipitate GVHD. This one study has evaluated the benefits of IFN therapy in HCV-infected SCT recipients, 8 and no experience has been published to date concerning combined treatment.
Since HCV-infected SCT recipients are at higher risk of earlier cirrhosis, evaluation of treatment regimens for HCV infection is critical for providing safe and effective treatment of this particular population.
Patients and methods

Patients
This retrospective single-center study was conducted in the Department of Bone Marrow Transplantation of the Hospital Saint Louis (Paris, France). All patients who underwent allogeneic bone marrow transplantation between November 1973 and January 1995 were evaluated for HCV infection. We have already published the long-term outcome of 96 HCV-infected patients following SCT. 3 In all, 36 of these patients were considered to require antiviral therapy according to the results of liver biopsy. In total, 22 were treated because there were no treatment contraindications. Patients, diseases and transplantation characteristics are summarized in Table 1 . The mean age of the patients at transplantation was 21.9 years (range, 11-41 years); 14 were male (63%) and eight (37%) were female. Details concerning transplant procedures and clinical care in our unit have already been described. 9, 10 Exclusion criteria All patients fulfilled the following criteria before HCV treatment: follow-up 42 years, donor-type chimerism, no chronic GVHD, no immunosuppressive therapy, no hypergammaglobulinemia or autoantibodies, no psychiatric disease, alcohol or drug consumption. Before HCV treatment, the serum creatinine level was required to be o1.5 times the upper normal limit. Patients were not treated if they had neutropenia (o1500 neutrophils/mm 3 ), thrombocytopenia (o100 000 platelets/mm 3 ) or anemia (o12 g of hemoglobin/dl in women and o13 g in men).
Treatment regimen
Prior to treatment, all patients had anti-HCV antibodies, detectable serum HCV RNA by PCR and fibrosis stage X1 with the presence of necroinflammation on liver biopsy (Knodell score). Patients were treated with IFN alone or with a combination of IFN or PEG IFN and RBV (a2aIFN; subcutaneous injections of 3 million units three times a week; PEGa2b IFN 1.5 mg/kg once a week; RBV 1000 mg oral daily for patients weighing o75 kg and 1200 mg for those weighing 475 kg). Since this is a retrospective study, the choice of the type of treatment related to the time of diagnosis of HCV-related complications. The great majority of patients receiving IFN alone were thus treated before 1998. From then on, we began treating our patients with combined therapy, PEG IFN being used from 2002. Duration of the treatment was 24 or 48 weeks for IFN monotherapy and 48 weeks for combined treatment.
Efficacy and safety
The efficacy endpoint was sustained virological response, defined by the absence of detectable serum HCV RNA by PCR 24 weeks after the end of treatment.
Safety was assessed by physical examination, laboratory tests and reports of adverse events. Clinic visits and laboratory tests were scheduled weekly during the 1st month and monthly thereafter. The following symptoms were recorded: fatigue, pyrexia, myalgia, insomnia, depression, irritability, headache, decreased appetite, arthralgia, thyroid problems and alopecia. Clinicians paid particular attention to GVHD recurrence. Laboratory tests included serum aspartate (AST), alanine (ALT) aminotransaminase, gamma glutamyl transferase (gGT), alkaline phosphatase bilirubin levels, hemoglobin, total white blood count, neutrophil and platelet counts. In patients with significant adverse clinical or biological events, the dose of IFN, PEG IFN and/or RBV was reduced to half the initial prescribed dose. After an attempt to use erythropoietin, RBV therapy was discontinued in patients with hemoglobin levels of o8.5 g/dl.
Results
Only 22/36 patients (61%) could be treated. Among 99 HCV-infected HCT recipients, 70 underwent liver biopsy because of persistent elevation of transaminases levels. In all, 29 patients had repeatedly normal transaminases and, therefore, were not evaluated by biopsy, since nontransplant patients with repeatedly normal transaminases usually have minimal liver lesions. 17 Among the 70 patients who had a liver biopsy, 36 showed fibrosis stage X1 (Knodell score) and therefore would have needed treatment. However, 14 patients were not treated for the following reasons: mixed chimerism (n ¼ 2), GVHD (n ¼ 6), thrombocytopenia (n ¼ 3), anemia (n ¼ 1) and patient refusal (n ¼ 2).
Better efficacy of combined therapy
In all, 22 patients received 41 treatment courses. The first course of antiviral therapy consisted in IFN alone in 17 Table 2 . A sustained virological response was obtained in 10% (2/ 20) of patients treated with IFN alone and in 20% (4/18) of patients treated either with IFN/RBV (n ¼ 9) or PEG IFN/ RBV (n ¼ 9). No predictive factors for response were found comparing the group of patients with, or without, sustained virological response. It is striking that among these six patients, four had received combination therapy either as a first-line (PEG IFN plus RBV: n ¼ 2) or as a second-line (IFN plus RBV: n ¼ 2) therapy. Then, two of four (50%) patients who were initially treated with the gold-standard treatment obtained sustained virological response.
Combined therapy led to more hematological toxicity
Therapy-related adverse effects are detailed in Table 3 . Clinical adverse events were comparable between both groups. More hematological complications were observed in patients receiving the combined therapy. Seven patients developed anemia while receiving RBV, while only one patient did so while receiving IFN alone. Four patients developed thrombocytopenia with the combination treatment (only one with IFN alone). Dose modification and/or erythropoietin treatment allowed continuation of RBV (only one patient stopped the treatment because of anemia). Nevertheless, most of the cases of thrombocytopenia led to treatment interruption (three out of four patients). Finally, in three patients treated with IFN alone, GVHD reoccurred.
Correlation between successful HCV therapy and long-term survival
It is noteworthy that all the six patients who achieved sustained virological responses were alive at the end of the study. Three patients out of the 16 patients who did not achieve sustained virological responses died because of HCV-related complications. In the group of patients who were not treated because of contraindications, we observed seven deaths in 14 patients, from which six were directly related to HCV. 
Discussion
In this study, we were able to treat only 22 of 36 SCT recipients who needed anti-HCV therapy because of liver lesions but who also had treatment contraindications. We obtained a sustained virological response in six out of 22 patients, four whom were treated with combination therapy. Although only a few patients were treated, the combination treatment seemed more effective in achieving sustained virological response. However, the combination therapy also resulted in more hematological complications. While anemia could be easily managed with dose modification and/or erythropoietin, thrombocytopenia mostly led to treatment interruption. To date, the gold-standard treatment in nontransplanted patients is the combination of PEG IFN and RBV. [4] [5] [6] [7] Sustained virological response in clinical trials is reported in approximately 80% of patients with HCV genotype 2 or 3, but in o50% in patients infected with HCV genotype 1. [5] [6] [7] Concerning immunocompromised individuals, HCV treatment is often associated with a poor response. Among 106 patients coinfected with HIV/HCV, only 16% had a sustained virological response mainly because of discontinuation due to adverse events. 11 In liver transplantation, PEG IFN and RBV treatment achieved virological response in nine out of 20 patients (45%). Treatment was withdrawn in four patients (20%) and the dose of PEG IFN and of RBV was reduced for six and 13 patients, respectively. 12 These observations are not only in agreement with our results but also emphasize the difficulty in obtaining a sustained virological response in such patients, mainly because of treatment discontinuation because of adverse events, and also partly because of difficulty in attaining a strong immune response. 13 Unfortunately, little has been published specifically concerning the treatment of HCV-infected SCT recipients. During the transplant period, RBV has been used to prevent immediate liver disease by HCV.
14 However, only one study reported the effects of standard IFN therapy in SCT recipients with only 10 patients completing the protocol, of whom five responded to treatment. 8 Four of these five patients had persistently undetectable HCV-RNA. In our study, standard IFN alone seems to be less effective. However, it is difficult to compare these two studies because of different patient characteristics (older age and greater severity of liver lesions in our cohort before treatment). Moreover, in the past year, with less sensitive HCV RNA PCR assays, some patients after IFN therapy could have been considered as sustained virological responders, while they had low HCV RNA viral loads. Preliminary data have been presented in abstract form evaluating the effect of both IFN alone or combined therapy in a large group of 70 SCT HCV-infected recipients. 15 Contrasting with our results, they suggest that the response rate to antiviral therapy was similar to other patient populations. Definitive results of this last study have not yet been published.
Thus, since SCT recipients seem to be at higher risk of earlier cirrhosis 3, 16 and immunosuppressed individuals are known to experience active hepatitis C with repeatedly normal transaminases, 17 histological liver evaluation should be performed in all patients to evaluate the stage of fibrosis and grade of necroinflammation. As was the case in our cohort, it is not surprising that approximately 30% of patients cannot be treated because of treatment conraindications. In candidates for HCV therapy, we demonstrate that SCT HCV-infected patients may benefit from combination treatment. The number of patients in our study is small. It is thus difficult to compare the combination of RBV with IFN standard or PEG IFN. The superiority of combined PEG IFN and RBV is now well established not only for immunocompetent patients 4-7 but also for immunocompromised HIV and HCV-infected patients. [18] [19] [20] As we observed no differences in toxicity between either combination (PEG IFN or standard IFN, in combination RBV), we advise clinicians to begin with full dose combined PEG IFN/RBV. We also showed that this treatment clearly needs close clinical and biological monitoring to prevent side effects. Patients presenting with anemia should receive erythropoietin or may benefit from dose modification to enable treatment to continue. In contrast, thrombocytopenia is more severe with combined therapy and mostly required treatment interruption.
In conclusion, HCV treatment of this particular population is essential because of HCV-related complications and poor survival of patients who were not treated because of treatment contraindications. This study highlights the potential of combined therapy in the context of allogeneic bone marrow transplantation, but the incidence of side effects necessitates a close monitoring. Prospective clinical trials are now crucial in assessing the efficacy and safety of HCV treatment in this patient population, as well as the histological benefit of the treatment, which is difficult to evaluate in a retrospective study.
